(Q44062377)

29 November 2017

title

Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. (English)

1 reference

29 November 2017

Simon Van Belle

1

1 reference

29 November 2017

Michael R Lichinitser

2

1 reference

29 November 2017

Rudolph M Navari

3

1 reference

29 November 2017

August M Garin

4

1 reference

29 November 2017

Marc L A Decramer

5

1 reference

29 November 2017

Alain Riviere

6

1 reference

29 November 2017

Myo Thant

7

1 reference

29 November 2017

Elmer Brestan

8

1 reference

29 November 2017

Binh Bui

9

1 reference

29 November 2017

Krista Eldridge

10

1 reference

29 November 2017

Marina De Smet

11

1 reference

29 November 2017

Nicole Michiels

12

1 reference

29 November 2017

Rick R Reinhardt

13

1 reference

29 November 2017

Alexandra D Carides

14

1 reference

29 November 2017

Judith K Evans

15

1 reference

29 November 2017

Barry J Gertz

16

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

29 November 2017

1 reference

29 November 2017

volume

94

1 reference

29 November 2017

issue

11

1 reference

29 November 2017

page(s)

3032-3041

1 reference

On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

Management of cisplatin-induced delayed emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

Proposal for classifying the acute emetogenicity of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

Enhancing the effectiveness of the specific serotonin antagonists. Combination antiemetic therapy with dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

Emesis as a Critical Problem in Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

7 January 2021

The management of chemotherapy-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

7 January 2021

Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: comparison of placebo vs. adrenocorticotropic hormone (ACTH)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

7 January 2021

Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

7 January 2021

Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

7 January 2021

Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

7 January 2021

A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

7 January 2021

Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

7 January 2021

Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

7 January 2021

The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

7 January 2021

Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

7 January 2021

Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10516

7 January 2021

Identifiers

DOI

10.1002/CNCR.10516

1 reference

29 November 2017

1 reference